

## Datasheet: AHP767

**BATCH NUMBER 167599**

<b>Description:</b>	RABBIT ANTI HUMAN EGF
<b>Specificity:</b>	EGF
<b>Format:</b>	Purified
<b>Product Type:</b>	Polyclonal Antibody
<b>Isotype:</b>	Polyclonal IgG
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry			▪	
Immunohistology - Frozen			▪	
Immunohistology - Paraffin (1)	▪			5.0ug/ml
ELISA	▪			0.5 - 2.0ug/ml
Immunoprecipitation			▪	
Western Blotting	▪			0.1 - 0.2ug/ml
Functional Assays	▪			<0.1ug/ml

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

**(1) This product requires heat-mediated pre-treatment of paraffin sections prior to staining. Citrate buffer pH 6.0 is recommended for this purpose**

<b>Target Species</b>	Human
<b>Product Form</b>	Purified IgG - lyophilized
<b>Reconstitution</b>	<p>Reconstitute with 0.1ml distilled water.</p> <p>For long term storage the addition of 0.09% sodium azide is recommended.</p> <p>N.B. For functional studies do not add azide.</p> <p>Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution.</p>

**Antiserum Preparation** Antisera to human EGF were raised by repeated immunisations of rabbits with highly purified antigen.  
Purified IgG prepared by affinity chromatography.

---

<b>Buffer Solution</b>	Phosphate buffered saline
------------------------	---------------------------

---

<b>Preservative Stabilisers</b>	None present.
---------------------------------	---------------

---

<b>Carrier Free</b>	Yes
---------------------	-----

---

<b>Approx. Protein Concentrations</b>	IgG concentration 1.0mg/ml after reconstitution
---------------------------------------	---

---

<b>Immunogen</b>	Recombinant human EGF ( <a href="#">PHP030A</a> ).
------------------	--

---

<b>External Database Links</b>	<b>UniProt:</b> <a href="#">P01133</a> <a href="#">Related reagents</a>  <b>Entrez Gene:</b> <a href="#">1950</a> EGF <a href="#">Related reagents</a>
--------------------------------	--

---

<b>RRID</b>	AB_2095966
-------------	------------

---

<b>Specificity</b>	<b>Rabbit anti Human EGF</b> recognizes human Epidermal Growth Factor, a potent stimulator and regulator of the proliferation of epidermal and epithelial cells, expressed by a variety of cells.
--------------------	---

The effects of EGF are initiated through tyrosine kinase activity, following the binding of EGF to the extracellular domain of the ~170 kDa EGF receptor (EGFR), which also binds other EGF-like ligands with high affinity, including TGF- $\alpha$  (transforming growth factor alpha), VGF (vaccinia virus growth factor) and Betacellulin, expressed in the pancreas, small intestine and by certain tumour cells ([Seno \*et al.\* 1996](#)). Receptor activation through EGF binding triggers several signal transduction pathways, including the JAK/STAT and P13K/AKT pathways.

---

<b>ELISA</b>	This purified human EGF antibody may be used in an indirect ELISA or as the capture reagent in a sandwich ELISA with a <a href="#">biotinylated human EGF antibody</a> (AHP767B) as the detection reagent and <a href="#">recombinant human EGF</a> (PHP030A) as the standard.
--------------	--

---

<b>Histology Positive Control Tissue</b>	Human kidney
--	--------------

---

<b>Western Blotting</b>	Rabbit anti human EGF may be used in Western Blotting applications under either reducing or non-reducing conditions with <a href="#">recombinant human EGF</a> (PHP030A) as the positive control.
-------------------------	---

---

<b>Further Reading</b>	1. Carpenter, G. & Cohen, S. (1990) Epidermal growth factor. <a href="#">J Biol Chem. 265 (14):</a>
------------------------	---

---

**Storage**

Prior to reconstitution store at -20°C.  
After reconstitution store at -20°C.

This product should be stored undiluted. Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

---

**Guarantee**

12 months from date of despatch

---

**Health And Safety  
Information**

Material Safety Datasheet documentation #10294 available at:  
<https://www.bio-rad-antibodies.com/SDS/AHP767>  
10294

---

**Regulatory**

For research purposes only

---

## Related Products

### Recommended Secondary Antibodies

Sheep Anti Rabbit IgG (STAR34...) [FITC](#)

Goat Anti Rabbit IgG (H/L) (STAR124...) [HRP](#)

Sheep Anti Rabbit IgG (STAR35...) [RPE](#)

Goat Anti Rabbit IgG (Fc) (STAR121...) [Biotin](#), [FITC](#), [HRP](#)

### Recommended Useful Reagents

[ANTIGEN RETRIEVAL BUFFER, pH8.0 \(BUF025A\)](#)

[TidyBlot WESTERN BLOT DETECTION REAGENT:HRP \(STAR209P\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M399146:220628'

**Printed on 29 Feb 2024**